Janssen Korea Introduces New Once-Daily Reminyl PR
Published: 2005-03-11 06:58:00
Updated: 2005-03-11 06:58:00
Janssen Korea announced early this week an availability of new, long-acting form of Reminyl PR (active ingredient: galantamine hydrobromide) for the treatment of mild to moderate Alzheimer's disease (AD) in the domestic market starting March.
According to the company, Reminyl PR capsules avail...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
